AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34348323 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone furoate nasal spray for 3 weeks followed by medical management for 3 months
Number of subjects: 31
Study 32456874 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin otic solution
Number of subjects: 136
Study 32456874 — intervention group
Group type: EXPERIMENTAL
Intervention: Gelatin sponge patch
Number of subjects: 136
Study 32456874 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous healing
Number of subjects: 136
Study 33966790 — intervention group
Group type: EXPERIMENTAL
Intervention: Training program consisting of eight interactive sessions based on a Nursing Module on abuse among women with mental illness
Number of subjects: 68
Study 33966790 — intervention group
Group type: EXPERIMENTAL
Intervention: Training program
Number of subjects: 68
Study 33966790 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 68
Study 35183000 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue adhesive (2-octylcyanoacrylate)
Number of subjects: 66
Study 35183000 — intervention group
Group type: COMPARATOR
Intervention: Metal staples
Number of subjects: 66
Study 34158387 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled Ankle Motion (CAM) boot
Number of subjects: 87
Study 34158387 — intervention group
Group type: COMPARATOR
Intervention: Above-knee plaster of Paris cast (AK-POP)
Number of subjects: 87
Study 32345699 — intervention group
Group type: EXPERIMENTAL
Intervention: isCGM
Number of subjects: 4
Study 32345699 — intervention group
Group type: COMPARATOR
Intervention: standard care
Number of subjects: 4
Study 32345699 — intervention group
Group type: EXPERIMENTAL
Intervention: ABC
Number of subjects: 4
Study 32345699 — intervention group
Group type: EXPERIMENTAL
Intervention: ABC+isCGM
Number of subjects: 4
Study 35644957 — intervention group
Group type: EXPERIMENTAL
Intervention: Mivacurium (0.25 mg/kg injected and continuously infused at 0.3 mg·kg‐1·h‐1)
Number of subjects: 56
Study 35644957 — intervention group
Group type: COMPARATOR
Intervention: Cisatracurium besylate (0.1 mg/kg injected, normal saline infused)
Number of subjects: 56
Study 32549996 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care plus with additional three‐monthly magnetic resonance imaging until remission up to 12 months
Number of subjects: 60
Study 32549996 — intervention group
Group type: COMPARATOR
Intervention: Magnetic resonance imaging at baseline and remission up to 12 months, with repeated foot temperature measurements and X‐rays (standard care plus)
Number of subjects: 60
Study 33431085 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD‐11 PTSD diagnosis
Number of subjects: 221
Study 33431085 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD‐11 CPTSD diagnosis
Number of subjects: 221
Study 34936269 — intervention group
Group type: EXPERIMENTAL
Intervention: Baixiao moxibustion and qiangshen shugan qiwei decoction (one dose daily)
Number of subjects: 120
Study 34936269 — intervention group
Group type: COMPARATOR
Intervention: qiangshen shugan qiwei decoction (one dose daily)
Number of subjects: 120
Study 35338035 — intervention group
Group type: EXPERIMENTAL
Intervention: Anifrolumab 300 mg
Number of subjects: 726
Study 35338035 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 726
Study 33373667 — intervention group
Group type: EXPERIMENTAL
Intervention: Point of care screening (POC)
Number of subjects: 0
Study 33373667 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct patient engagement (DPE)
Number of subjects: 0
Study 36084331 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional ILM peeling
Number of subjects: 50
Study 36084331 — intervention group
Group type: COMPARATOR
Intervention: Inverted flap technique
Number of subjects: 50
Study 36084331 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study 33229930 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine group: perioperative intravenous lidocaine infusion, plus PCA with morphine
Number of subjects: 75
Study 33229930 — intervention group
Group type: COMPARATOR
Intervention: Epidural group: PCA with bupivacaine
Number of subjects: 75
Study 33229930 — intervention group
Group type: COMPARATOR
Intervention: Opioid group: patient‐controlled analgesia (PCA) with morphine
Number of subjects: 75
Study 34213858 — intervention group
Group type: EXPERIMENTAL
Intervention: MMWR (Mindfulness-Based Intervention)
Number of subjects: 200
Study 32185760 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemia-modified albumin (IMA) and IMA/albumin ratio (IMAR) in the 30-min shock group
Number of subjects: 0
Study 32185760 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemia-modified albumin (IMA) and IMA/albumin ratio (IMAR) in the 60-min shock group
Number of subjects: 0
Study 32185760 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 32185760 — intervention group
Group type: EXPERIMENTAL
Intervention: Shock groups (mild and severe)
Number of subjects: 0
Study 32185760 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of biomarkers with HS-induced damage
Number of subjects: 0
Study 34098845 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual fortification (IF) of mother’s breast milk
Number of subjects: 60
Study 34098845 — intervention group
Group type: COMPARATOR
Intervention: Standard fortification (SF) of mother’s breast milk
Number of subjects: 60
Study 34564996 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomograms for predicting overall survival (OS)
Number of subjects: 948
Study 34564996 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomograms for predicting cancer-specific survival (CSS)
Number of subjects: 948
Study 34564996 — intervention group
Group type: EXPERIMENTAL
Intervention: Independent prognostic factors for OS
Number of subjects: 948
Study 34564996 — intervention group
Group type: EXPERIMENTAL
Intervention: Independent prognostic factors for CSS
Number of subjects: 948
Study 34280012 — intervention group
Group type: EXPERIMENTAL
Intervention: GST-HG141 (300 mg)
Number of subjects: 50
Study 34280012 — intervention group
Group type: EXPERIMENTAL
Intervention: GST-HG141 (50 mg)
Number of subjects: 50
Study 34280012 — intervention group
Group type: EXPERIMENTAL
Intervention: GST-HG141 (100 mg)
Number of subjects: 50
Study 34280012 — intervention group
Group type: COMPARATOR
Intervention: GST-HG141
Number of subjects: 50
Study 32334845 — intervention group
Group type: EXPERIMENTAL
Intervention: Biosimilar BE1040V plus FOLFIRI-3 (5 mg/kg IV every 2 weeks for 1 year)
Number of subjects: 126
Study 32334845 — intervention group
Group type: COMPARATOR
Intervention: Reference drug plus FOLFIRI-3 (dosage not specified, every 2 weeks for 1 year)
Number of subjects: 126
Study 35421848 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical cancer survivor's story (short film)
Number of subjects: 2175
Study 35421848 — intervention group
Group type: COMPARATOR
Intervention: Nothing (control group)
Number of subjects: 2175
Study 34878990 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile app intervention (app group)
Number of subjects: 83
Study 34878990 — intervention group
Group type: COMPARATOR
Intervention: Usual care (no-app group)
Number of subjects: 83
Study 32013647 — intervention group
Group type: EXPERIMENTAL
Intervention: PAD facilitation by peer support specialist
Number of subjects: 145
Study 32013647 — intervention group
Group type: COMPARATOR
Intervention: PAD facilitation by non-peer ACT team clinician
Number of subjects: 145
Study 33060092 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based screening programme
Number of subjects: 0
Study 33060092 — intervention group
Group type: COMPARATOR
Intervention: No additional intervention (control)
Number of subjects: 0
Study 35157527 — intervention group
Group type: EXPERIMENTAL
Intervention: Salt loading (3,900 mg sodium for 10 days)
Number of subjects: 20
Study 35157527 — intervention group
Group type: COMPARATOR
Intervention: Placebo (10 days)
Number of subjects: 20
Study 33685234 — intervention group
Group type: EXPERIMENTAL
Intervention: PE+T+PP (phenylephrine + tropicamide + proparacaine)
Number of subjects: 63
Study 33685234 — intervention group
Group type: COMPARATOR
Intervention: T+PP (tropicamide + proparacaine)
Number of subjects: 63
Study 32248329 — intervention group
Group type: EXPERIMENTAL
Intervention: BIM23B065
Number of subjects: 0
Study 34759933 — intervention group
Group type: COMPARATOR
Intervention: Eptinezumab (10 to 1000 mg, administered intravenously for up to 4 doses at 12-week intervals)
Number of subjects: 2076
Study 32931324 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive overdose education and naloxone distribution (OEND) training
Number of subjects: 787
Study 33819350 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula method
Number of subjects: 130
Study 33819350 — intervention group
Group type: COMPARATOR
Intervention: Common method
Number of subjects: 130
Study 32102054 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (SB) supplementation at a dosage of 0.3 g·kg BM in gelatine capsules
Number of subjects: 13
Study 32102054 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (SB) supplementation
Number of subjects: 13
Study 33905287 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Therapy for Improving Emotional Acceptance and Regulatory Skills in Adults with ADHD (GEARS)
Number of subjects: 226
Study 32484261 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIT)
Number of subjects: 62
Study 32484261 — intervention group
Group type: COMPARATOR
Intervention: Moderate Intensity Continuous Training
Number of subjects: 62
Study 36197520 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 75
Study 36197520 — intervention group
Group type: EXPERIMENTAL
Intervention: Duodenal switch (DS)
Number of subjects: 75
Study 34006075 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% deproteinised bovine bone matrix grafts (DBBM)
Number of subjects: 40
Study 34006075 — intervention group
Group type: COMPARATOR
Intervention: 100% autogenous bone grafts (AB)
Number of subjects: 40
Study 32794282 — intervention group
Group type: EXPERIMENTAL
Intervention: Microwave-assisted pasteurized fried rice (MAPS)
Number of subjects: 2
Study 32794282 — intervention group
Group type: COMPARATOR
Intervention: Control fried rice (cooked but not MAPS-processed)
Number of subjects: 2
Study 32657198 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapy Behavior Scale (TBS) Version 2.2
Number of subjects: 10
Study 33044437 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate beverage (1.2 g·min‐1 glucose) after breakfast omission
Number of subjects: 11
Study 33044437 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate beverage (1.2 g·min‐1 glucose) after breakfast consumption
Number of subjects: 11
Study 33044437 — intervention group
Group type: COMPARATOR
Intervention: Placebo beverage after breakfast omission
Number of subjects: 11
Study 33044437 — intervention group
Group type: COMPARATOR
Intervention: Placebo beverage after breakfast consumption
Number of subjects: 11
Study 33044437 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate beverage after breakfast consumption
Number of subjects: 11
Study 33044437 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate beverage after breakfast omission
Number of subjects: 11
Study 35793536 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative condition (consistent negative statement about e‐cigarette harms)
Number of subjects: 702
Study 35793536 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking Risk + Conflict condition (statement of the risks of smoking followed by a harm reduction statement from one public health body and a negative statement from another)
Number of subjects: 702
Study 35793536 — intervention group
Group type: EXPERIMENTAL
Intervention: Conflict condition (harm reduction statement from one public health body and a negative statement from another)
Number of subjects: 702
Study 35793536 — intervention group
Group type: COMPARATOR
Intervention: Harm Reduction condition (consistent harm reduction statement from two different public health bodies)
Number of subjects: 702
Study 32131476 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardio-protective diet and physical exercise
Number of subjects: 51
Study 32131476 — intervention group
Group type: COMPARATOR
Intervention: Baseline selenium status
Number of subjects: 51
Study 32131476 — intervention group
Group type: EXPERIMENTAL
Intervention: SELENOP concentration
Number of subjects: 51
Study 32131476 — intervention group
Group type: EXPERIMENTAL
Intervention: GPx activity
Number of subjects: 51
Study 33290360 — intervention group
Group type: EXPERIMENTAL
Intervention: Notched music therapy
Number of subjects: 75
Study 33290360 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional music therapy
Number of subjects: 75
Study 33290360 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling
Number of subjects: 75
Study 33233750 — intervention group
Group type: EXPERIMENTAL
Intervention: 14-week teacher training program
Number of subjects: 141
Study 33233750 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 141
Study 35641257 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated liposomal doxorubicin (PLD)
Number of subjects: 60
Study 32312357 — intervention group
Group type: EXPERIMENTAL
Intervention: Unified Protocol (UP)
Number of subjects: 223
Study 32312357 — intervention group
Group type: COMPARATOR
Intervention: Symptom-focused CBT
Number of subjects: 223
Study 32312357 — intervention group
Group type: COMPARATOR
Intervention: Waitlist Control (WL)
Number of subjects: 223
Study 32779529 — intervention group
Group type: EXPERIMENTAL
Intervention: PEOL Care Index instrument
Number of subjects: 43
Study 35064870 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract (GBE) intervention group
Number of subjects: 0
Study 35064870 — intervention group
Group type: COMPARATOR
Intervention: Placebo control group
Number of subjects: 0
Study 34613379 — intervention group
Group type: EXPERIMENTAL
Intervention: Early physical therapy (PT)
Number of subjects: 204
Study 34613379 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 204
Study 33909355 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture plus medication
Number of subjects: 134
Study 33909355 — intervention group
Group type: COMPARATOR
Intervention: Medication
Number of subjects: 134
Study 35069580 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG vaccination
Number of subjects: 0
Study 32060567 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular treatment combined with intravenous alteplase
Number of subjects: 275
Study 32060567 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular treatment as single treatment
Number of subjects: 275
Study 35896281 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib 15 mg once daily
Number of subjects: 187
Study 35896281 — intervention group
Group type: COMPARATOR
Intervention: Upadacitinib (after switching from placebo)
Number of subjects: 187
Study 35896281 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous upadacitinib
Number of subjects: 187
Study 35896281 — intervention group
Group type: COMPARATOR
Intervention: Placebo-to-upadacitinib switch
Number of subjects: 187
Study 35896281 — intervention group
Group type: EXPERIMENTAL
Intervention: Total group
Number of subjects: 187
Study 35896281 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 187
Study 32885455 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk Group (carried both rs4880 and rs1050450 at-risk alleles)
Number of subjects: 34
Study 32885455 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk Group
Number of subjects: 34
Study 32885455 — intervention group
Group type: COMPARATOR
Intervention: Nonrisk Group
Number of subjects: 34
Study 32761500 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type B (BTX‐B)
Number of subjects: 20
Study 32761500 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 32761500 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 20
Study 34587807 — intervention group
Group type: EXPERIMENTAL
Intervention: Medial patellofemoral ligament reconstruction (MPFLr)
Number of subjects: 202
Study 34587807 — intervention group
Group type: EXPERIMENTAL
Intervention: MPFLr + tibial tubercle distalization (TTD)
Number of subjects: 202
Study 34587807 — intervention group
Group type: EXPERIMENTAL
Intervention: Trochleoplasty + TTD
Number of subjects: 202
Study 34587807 — intervention group
Group type: EXPERIMENTAL
Intervention: Trochleoplasty
Number of subjects: 202
Study 32905673 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous high-flow oxygen therapy with frequency of suctioning as the indicator of readiness for decannulation
Number of subjects: 330
Study 32905673 — intervention group
Group type: COMPARATOR
Intervention: 24-hour capping trial plus intermittent high-flow oxygen therapy
Number of subjects: 330
Study 34808142 — intervention group
Group type: EXPERIMENTAL
Intervention: R+L− stimulation (tDCS over bilateral DLPFC)
Number of subjects: 70
Study 34808142 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 70
Study 34019819 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel (75 mg/m2 intravenous), carboplatin (area under the concentration–time curve 6 mg/mL per min intravenous), trastuzumab (subcutaneous 600 mg fixed dose), and pertuzumab (intravenous 840 mg loading dose, 420 mg maintenance doses)
Number of subjects: 356
Study 34019819 — intervention group
Group type: COMPARATOR
Intervention: Trastuzumab and pertuzumab (with letrozole or tamoxifen for hormone receptor-positive patients)
Number of subjects: 356
Study 32276003 — intervention group
Group type: EXPERIMENTAL
Intervention: GINA + FeNO group
Number of subjects: 176
Study 32276003 — intervention group
Group type: COMPARATOR
Intervention: GINA group
Number of subjects: 176
Study 36105446 — intervention group
Group type: EXPERIMENTAL
Intervention: Omaha system‐based comprehensive nursing
Number of subjects: 60
Study 34238788 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex reconstruction (flap or graft) performed by 6 surgeons
Number of subjects: 338
Study 32755237 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic growth factors injection
Number of subjects: 150
Study 32755237 — intervention group
Group type: COMPARATOR
Intervention: Saline 0.9% injection
Number of subjects: 150
Study 34530020 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab plus background nasal mometasone therapy for 28 weeks
Number of subjects: 249
Study 34530020 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab (after switching from placebo)
Number of subjects: 249
Study 34530020 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab discontinuation
Number of subjects: 249
Study 34530020 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety profile of omalizumab
Number of subjects: 249
Study 33786690 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically predicted serum urate levels
Number of subjects: 110347
Study 34894861 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training and supplementation (whey protein and vitamin D)
Number of subjects: 30
Study 34894861 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training and placebo
Number of subjects: 30
Study 34894861 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 30
Study 33625693 — intervention group
Group type: EXPERIMENTAL
Intervention: Citrate buffer during high volume on-line hemodiafiltration (OL-HDF)
Number of subjects: 0
Study 33625693 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 33711170 — intervention group
Group type: EXPERIMENTAL
Intervention: Extraradicular biofilm samples
Number of subjects: 18
Study 33711170 — intervention group
Group type: COMPARATOR
Intervention: Periapical lesions
Number of subjects: 18
Study 32331026 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg SPN-812
Number of subjects: 313
Study 32331026 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg SPN-812
Number of subjects: 313
Study 32331026 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 313
Study 35696023 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen Peptide (CP) at 5.0 g/day for 3 months
Number of subjects: 44
Study 35696023 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen Peptide Fermented with Aspergillus sojae (FCP) at 5.0 g/day for 3 months
Number of subjects: 44
Study 35696023 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL) at 5.0 g/day for 3 months
Number of subjects: 44
Study 33429063 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide (1.8 mg sc)
Number of subjects: 51
Study 33429063 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin (100 mg)
Number of subjects: 51
Study 33429063 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 34414808 — intervention group
Group type: EXPERIMENTAL
Intervention: Making Your Wishes Known (MYWK) together with loved one
Number of subjects: 246
Study 34414808 — intervention group
Group type: COMPARATOR
Intervention: Other control groups
Number of subjects: 246
Study 34414808 — intervention group
Group type: EXPERIMENTAL
Intervention: MYWK Together
Number of subjects: 246
Study 33434087 — intervention group
Group type: EXPERIMENTAL
Intervention: Listening to music during cesarean section and postpartum (Group 3)
Number of subjects: 185
Study 33434087 — intervention group
Group type: EXPERIMENTAL
Intervention: Listening to music during cesarean section (Group 2)
Number of subjects: 185
Study 33434087 — intervention group
Group type: COMPARATOR
Intervention: No music (Group 1)
Number of subjects: 185
Study 33434087 — intervention group
Group type: EXPERIMENTAL
Intervention: Listening to music in a private ward
Number of subjects: 185
Study 33434087 — intervention group
Group type: EXPERIMENTAL
Intervention: Mothers with income <20,000 baht, lower than university education, planned pregnancy, first pregnancy, and stayed in a private ward
Number of subjects: 185
Study 33313728 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated sequenced-care pathway
Number of subjects: 1680
Study 33313728 — intervention group
Group type: COMPARATOR
Intervention: Coordinated pain navigator pathway
Number of subjects: 1680
Study 33313728 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional surveys for a subset of veterans
Number of subjects: 1680
Study 33313728 — intervention group
Group type: EXPERIMENTAL
Intervention: Both pathways
Number of subjects: 1680
Study 34062085 — intervention group
Group type: EXPERIMENTAL
Intervention: Qingrun yogurt (250 g) once daily for 12 weeks
Number of subjects: 136